Functional Fluidics was honored to participate in this event

organized by The New York Academy of Sciences in October of 2017:

Overview

Every year, more than 300,000 people are born with sickle cell disease (SCD), a blood disorder marked by frequent vaso-occlusive crises (VOC) in which patients experience fatigue and extreme pain. These crises can lead to organ damage and in the long term, early mortality. To date, the FDA has only approved two treatments for the disease. But improved insight into the complex pathophysiology of SCD has led to the recent development of diverse approaches for treatment, including inhibition of hemoglobin polymerization, prevention and treatment of vaso-occlusive events, and disease corrective gene therapy approaches.

On October 24, 2017, the New York Academy of Sciences and the Biochemical Pharmacology Discussion Group presented Towards Transformative Therapies for Sickle Cell Disease. The event brought together leading researchers and scientists from across the field to discuss key biological mechanisms of the disease and innovative new approaches for treatment, while underscoring the importance of the patient experience.

New York Academy of Sciences members can download the event report by following this link

Overview

This short video describes the origins of the company, based on research in the Hines Lab at Wayne State University. We have developed a suite of assays that address the need for better ways to assess blood function, starting with the experience of Dr. Hines as a Pediatric ICU Physician at Detroit Medical Center.